Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 76 to 100 of 410

Guidance and quality standards awaiting development
Title	Type
Delandistrogene moxeparvovec for treating Duchenne muscular dystrophy in children 4 to 7 years [ID3897]	Technology appraisal guidance
Delgocitinib for Chronic Hand Eczema [ID6688]	Technology appraisal guidance
Denosumab biosimilar for Giant cell-rich tumours of bone or Skeletal events in bone malignancies [TSID12150]	Technology appraisal guidance
Depemokimab for treating eosinophilic granulomatosis with polyangiitis [TSID12383]	Technology appraisal guidance
Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over [ID6160]	Technology appraisal guidance
Deucravacitinib for treating active Sjogren's disease [ID6715]	Technology appraisal guidance
Deucravacitinib for treating systemic lupus erythematosus [TSID12405]	Technology appraisal guidance
Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery [ID1154]	Technology appraisal guidance
Diabetic foot problems: prevention and management - topical wound oxygen therapy for diabetic foot ulcers	NICE guideline
Divarasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer	Technology appraisal guidance
Diverticular disease	Quality standard
Donanemab for reducing the risk of mild cognitive impairment in preclinical Alzheimer's disease [ID6675]	Technology appraisal guidance
Doravirine-islatravir for previously untreated HIV-1 infection	Technology appraisal guidance
Doravirine–islatravir for treating HIV-1 in people with virological suppression on antiretroviral therapy	Technology appraisal guidance
Doravirine–islatravir for treating HIV-1 in people with virological suppression on bictegravir, emtricitabine and tenofovir alafenamide combination treatment	Technology appraisal guidance
Dorocubicel for treating haematological cancer when a suitable donor is unavailable for an allogeneic haematopoietic stem cell transplant [ID6521]	Technology appraisal guidance
Dostarlimab for treating primary advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency when systemic treatment is suitable [ID6660]	Technology appraisal guidance
Dostarlimab for untreated locally advanced rectal cancer with high microsatellite instability or mismatch repair deficiency [ID6747]	Technology appraisal guidance
Doxecitine–doxribtimine for treating thymidine kinase 2 deficiency in people of any age who had symptoms before 13 years [ID6484]	Technology appraisal guidance
Dulaglutide for treating type 2 diabetes [ID1451]	Technology appraisal guidance
Dupilumab for treating bullous pemphigoid [ID6479]	Technology appraisal guidance
Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years [ID6492]	Technology appraisal guidance
Durvalumab (Imfinzi) +/- bevacizumab (Avastin) for hepatocellular carcinoma [TSID10736]	Technology appraisal guidance
Durvalumab for adjuvant treatment of hepatocellular carcinoma at high risk of recurrence after curative liver resection or ablation [ID6206]	Technology appraisal guidance
Durvalumab with BCG for treating high-risk non-muscle-invasive bladder cancer after resection of papillary tumours in people previously untreated with BCG [ID5080]	Technology appraisal guidance

Results per page

10
25
50
All